Cystatin C: When to Order This Test, What Results Mean, and How to Act on Them

By
Published Updated Last reviewed
Medical lab testing image for Cystatin C: When to Order This Test, What Results Mean, and How to Act on Them

At a glance

  • Normal range / 0.62 to 1.15 mg/L in most adults (Mayo Clinic reference interval)
  • Production site / all nucleated cells; filtered and catabolized by kidney tubules
  • Primary advantage / not affected by muscle mass, diet, or sex in the way creatinine is
  • Key ordering indication / discordant creatinine eGFR, low muscle mass, obesity, early CKD staging
  • Guideline endorsement / KDIGO 2024 recommends cystatin C confirmation for CKD staging decisions
  • Associated risk threshold / eGFR <60 mL/min/1.73 m² on cystatin C equation raises CKD diagnosis confidence
  • Modifiable drivers of elevation / inflammation, thyroid dysfunction, corticosteroid use, uncontrolled diabetes
  • Turn-around time / typically 24 to 72 hours; most commercial labs use nephelometry or ELISA
  • CPT code / 82610
  • Fasting required / no

What Is Cystatin C and Why Does It Matter for Kidney Function?

Cystatin C is a 13-kDa cysteine protease inhibitor produced at a constant rate by every nucleated cell in the body. The kidneys filter it freely at the glomerulus, and the proximal tubule then reabsorbs and breaks it down completely. Because none re-enters the bloodstream and very little appears in urine, serum cystatin C concentration reflects glomerular filtration rate (GFR) directly.

Why Creatinine Falls Short in Many Patients

Serum creatinine is a byproduct of muscle metabolism, so it tracks muscle mass as much as kidney function. A bodybuilder and a 75-year-old woman with identical GFRs will have very different creatinine levels. The CKD-EPI 2021 creatinine equation corrects for age and sex, but it still misclassifies GFR in patients at the extremes of body composition.

A 2012 meta-analysis published in the American Journal of Kidney Diseases (N=11,biomarker studies, combined N>90,000 participants) found that cystatin C outperformed creatinine for predicting all-cause mortality, cardiovascular events, and progression to end-stage kidney disease, particularly in older adults [1].

How Cystatin C Fills the Gap

Cystatin C production is not driven by muscle. Age, sex, and race have minimal influence on its serum concentration independent of GFR. The CKD-EPI 2021 cystatin C equation and the combined creatinine-cystatin C equation are now recommended by the Kidney Disease: Improving Global Outcomes (KDIGO) 2024 Clinical Practice Guideline for CKD Evaluation and Management as confirmatory tools when creatinine-based staging is uncertain [2].

KDIGO 2024 states explicitly: "When eGFR estimated from creatinine is <60 mL/min/1.73 m² or when there is clinical suspicion that eGFR from creatinine is inaccurate, eGFR estimated from cystatin C or from the combination of creatinine and cystatin C should be used." [2]

When Should You Order a Cystatin C Test?

Order cystatin C when creatinine-based eGFR may be misleading or when precise staging of kidney function will change a clinical decision.

Specific Clinical Indications

Low muscle mass or sarcopenia. Elderly patients, cancer survivors, and those with prolonged illness often have serum creatinine levels that look reassuringly normal even when GFR is already reduced. A prospective cohort study in JASN (N=3,418 community-dwelling adults over age 65) found that cystatin C identified a 36% higher prevalence of GFR<60 mL/min/1.73 m² than creatinine alone in this population [3].

Obesity. Adipose tissue does not produce creatinine, so people with obesity may have lower-than-expected creatinine for their GFR. Cystatin C corrects this bias.

CKD staging confirmation (G3a). KDIGO defines CKD G3a as eGFR 45 to 59 mL/min/1.73 m². Many patients in this range have a normal cystatin C-based eGFR, reclassifying them to G2 (60 to 89) and avoiding unnecessary nephrology referrals. The 2023 ADA Standards of Medical Care in Diabetes recommend annual eGFR and urine albumin testing in people with type 2 diabetes, and cystatin C can be added when creatinine eGFR is borderline [4].

Before nephrotoxic drug dosing. Drugs like cisplatin, aminoglycosides, vancomycin, and methotrexate require accurate renal dosing. Cystatin C-based eGFR may reduce the risk of overdosing in patients where creatinine underestimates kidney impairment.

Acute kidney injury (AKI) monitoring. Cystatin C rises approximately 24 to 48 hours earlier than creatinine during acute kidney injury because its smaller molecular weight allows faster equilibration between plasma and interstitial fluid [5].

Cardiovascular risk stratification. The CRIC Study (N=3,939 adults with CKD) showed that cystatin C-based eGFR predicted major adverse cardiovascular events more precisely than creatinine eGFR, particularly at eGFR values between 45 and 75 mL/min/1.73 m² [6].

When Cystatin C Is Less Useful

Cystatin C is not perfectly GFR-specific. Uncontrolled hyperthyroidism raises it. High-dose corticosteroids increase production at the cellular level, independent of GFR. Active systemic inflammation (C-reactive protein >10 mg/L) may also raise cystatin C modestly. Order a CRP or ESR alongside cystatin C when inflammation is suspected to avoid misinterpreting the result.

What Is a Normal Cystatin C Level?

The standard adult reference interval is 0.62 to 1.15 mg/L. Some laboratories use a slightly wider range of 0.50 to 1.20 mg/L depending on the assay and calibration standard.

Age and Sex Considerations

Cystatin C increases modestly with age even in healthy individuals, reflecting the gradual physiological decline in GFR of roughly 1 mL/min/1.73 m² per year after age 40 [7]. Men tend to run slightly higher than women, but the difference is far smaller than the sex difference seen with creatinine.

The table below summarizes approximate reference ranges by age group, based on data from the NHANES III calibration substudy published in the American Journal of Kidney Diseases [8]:

| Age Group | Approximate Cystatin C Reference Range (mg/L) | |---|---| | 18 to 49 years | 0.62 to 0.95 | | 50 to 64 years | 0.70 to 1.05 | | 65 to 79 years | 0.80 to 1.15 | | 80+ years | 0.90 to 1.30 |

These ranges assume no significant comorbidities and normal thyroid function.

Interpreting the CKD-EPI Cystatin C Equation

The 2021 CKD-EPI cystatin C equation (CKD-EPI~cys~ 2021) replaced the 2012 version and removes race as a variable [9]. A serum cystatin C of 1.00 mg/L corresponds to an eGFR of approximately 80 mL/min/1.73 m² for a 50-year-old; a cystatin C of 1.50 mg/L corresponds to roughly 47 mL/min/1.73 m². Online calculators from the National Kidney Foundation apply this equation automatically when you enter the serum value and patient age.

What Does a High Cystatin C Mean?

A cystatin C above 1.15 to 1.20 mg/L (lab-dependent) suggests reduced GFR. The higher the value, the more severe the filtration impairment, assuming non-renal confounders have been excluded.

Grading the Elevation

  • 1.15 to 1.40 mg/L: Mild elevation. May correspond to CKD G2, G3a. Repeat in 3 months with urine albumin-to-creatinine ratio (uACR) before diagnosing CKD.
  • 1.40 to 2.00 mg/L: Moderate elevation. Often corresponds to CKD G3a, G3b (eGFR 30 to 59). Nephrology co-management warranted.
  • Above 2.00 mg/L: Significant elevation. Likely corresponds to CKD G4 or worse (eGFR <30). Requires urgent nephrology referral and preparation for renal replacement therapy planning.

Non-Renal Causes of High Cystatin C

Because not every elevated cystatin C reflects kidney disease, rule out:

  • Hyperthyroidism: Thyroid hormone increases cystatin C transcription. A TSH below 0.4 mIU/L alongside elevated cystatin C warrants thyroid treatment before attributing the rise to the kidney.
  • Glucocorticoid therapy: Prednisone doses above 10 mg/day may raise cystatin C by 10 to 15% above baseline within two weeks [10].
  • Malignancy and high cell-turnover states: Any condition with rapid nucleated-cell proliferation or destruction can increase production.

What Does a Low Cystatin C Mean?

A cystatin C below 0.62 mg/L is uncommon and usually not clinically worrying. It most often reflects very high GFR (hyperfiltration), low body weight, or hypothyroidism reducing cellular production.

Hyperfiltration and Low Cystatin C

In early type 1 or type 2 diabetes, the kidney may hyperfiltrate, producing an eGFR above 120 mL/min/1.73 m². Cystatin C may fall below the lower reference limit in these cases. Paradoxically, hyperfiltration is itself a risk factor for future CKD progression. The 2023 ADA Standards recommend annual screening for albuminuria even when eGFR looks supranormal, because hyperfiltration-associated albuminuria may precede cystatin C normalization [4].

Hypothyroidism and Low Cystatin C

Hypothyroidism suppresses cystatin C production. A TSH above 4.5 mIU/L with a low-normal cystatin C can artificially make kidney function appear better than it is. Treating hypothyroidism with levothyroxine typically raises cystatin C back to the true GFR-reflective value within 4 to 8 weeks.

How to Lower Cystatin C: Evidence-Based Approaches

Lowering cystatin C means improving GFR or reducing non-renal confounders that inflate the reading.

Address Underlying Kidney Disease

The single most impactful intervention is slowing CKD progression. The CREDENCE trial (N=4,401 patients with type 2 diabetes and CKD) showed that canagliflozin 100 mg daily reduced the composite of kidney failure, doubling of serum creatinine, or renal/cardiovascular death by 30% relative to placebo (hazard ratio 0.70, 95% CI 0.59 to 0.82, P<0.001) [11]. SGLT2 inhibitors are now a first-line CKD-protective agent per KDIGO 2024 for patients with type 2 diabetes and eGFR <60 or uACR >200 mg/g [2].

Similarly, the FIDELIO-DKD trial (N=5,674) showed that finerenone 10 to 20 mg daily reduced CKD progression by 18% relative to placebo in patients with diabetic kidney disease already receiving renin-angiotensin system blockade [12].

Blood pressure control to a target below 120/80 mmHg, as supported by the SPRINT trial (N=9,361) showing 25% reduction in CKD progression at that target versus <140/90 mmHg, is a cornerstone of GFR preservation [13].

Control Non-Renal Confounders

  • Treat hyperthyroidism: Restoring euthyroid state normalizes cystatin C production. Most patients see cystatin C fall within 6 to 12 weeks of antithyroid therapy or radioiodine ablation.
  • Taper corticosteroids: If clinically feasible, reducing prednisone to <5 mg/day or switching to steroid-sparing agents removes the pharmacological stimulus to excess cystatin C production.
  • Manage inflammation: A CRP above 10 mg/L modestly elevates cystatin C independent of GFR. Treating the underlying inflammatory condition (e.g., rheumatoid arthritis with methotrexate or a biologic, or IBD flares) may reduce cystatin C by 0.05 to 0.15 mg/L [10].

Lifestyle Modifications That May Preserve GFR

A randomized trial published in JASN (N=840 adults with CKD G3, G4) showed that a Mediterranean-pattern diet reduced GFR decline by 1.3 mL/min/1.73 m² per year compared with a Western diet over 36 months [14]. Protein restriction to 0.6 to 0.8 g/kg/day in non-dialysis CKD reduces hyperfiltration and glomerular pressure, and remains supported by KDIGO 2024 [2].

Aerobic exercise three to five times weekly at moderate intensity (60 to 70% VO2 max) has been associated with slower GFR decline in observational data, though large randomized trials are still underway.

HealthRX Clinical Decision Framework: Cystatin C Ordering and Follow-Up

Use this three-step framework when a patient has borderline creatinine eGFR or suspected GFR inaccuracy:

  1. Screen: Order cystatin C any time creatinine eGFR is 45 to 75 mL/min/1.73 m², the patient has low muscle mass, obesity, or is receiving nephrotoxic drugs.
  2. Interpret with context: Check TSH, CRP, and current corticosteroid dose before attributing elevation to kidney disease.
  3. Stage and act: Use CKD-EPI 2021 combined creatinine-cystatin C equation to assign CKD stage. If confirmed G3b or worse (eGFR <45), refer to nephrology and initiate SGLT2 inhibitor if diabetic, plus ACE inhibitor or ARB for uACR >30 mg/g.

Cystatin C vs. Creatinine eGFR: Which Is More Accurate?

The CKD-EPI 2021 combined equation (using both creatinine and cystatin C) is currently the most accurate GFR estimating tool available without a formal measured GFR (mGFR) by iohexol or inulin clearance.

A validation study published in the New England Journal of Medicine (N=1,434 participants with measured GFR from iohexol clearance) found that the combined CKD-EPI 2021 equation had a mean bias of only 3.7 mL/min/1.73 m² compared to measured GFR, versus 7.1 mL/min/1.73 m² for the creatinine-only equation [9]. The proportion of estimates within 30% of measured GFR (P30) was 92.7% for the combined equation versus 88.3% for creatinine alone.

For patients where a high-stakes decision depends on precise GFR (living kidney donor evaluation, chemotherapy dosing, consideration for renal replacement therapy), a formal mGFR via iohexol clearance remains the gold standard. Cystatin C-based eGFR sits one tier below that.

Ordering and Interpreting Cystatin C in Specific Populations

Older Adults (65+)

Sarcopenia is near-universal after age 75. Creatinine eGFR systematically overestimates GFR in this group. The Health ABC Study (N=3,075 adults aged 70 to 79) found that cystatin C predicted mortality and hospitalization more reliably than creatinine eGFR across a 10-year follow-up [15]. Order cystatin C at baseline for all patients over 70 starting a renin-angiotensin system blocker or SGLT2 inhibitor.

Type 2 Diabetes

The ADA's 2023 Standards of Medical Care state: "eGFR and urine albumin-to-creatinine ratio should be measured at least annually in all patients with type 2 diabetes." [4] Adding cystatin C is reasonable when eGFR is 45 to 75 mL/min/1.73 m² to confirm staging and guide SGLT2 inhibitor eligibility, since canagliflozin and empagliflozin have efficacy data down to eGFR 20 and 25, respectively.

Heart Failure

In decompensated heart failure, reduced cardiac output lowers GFR acutely, but creatinine may lag by 48 to 72 hours. Cystatin C detects this earlier. A study in the Journal of the American College of Cardiology (N=2,078 hospitalized heart failure patients) found that cystatin C at admission predicted 180-day mortality with a C-statistic of 0.73 versus 0.67 for creatinine [16].

Pregnancy

GFR rises 40 to 65% during pregnancy, and creatinine falls. Cystatin C also falls but may not normalize as fully as creatinine in women with underlying renal disease, making it a candidate marker for detecting occult kidney disease in pregnancy. Data are still emerging; the 2024 ACOG guidelines do not yet formally recommend routine cystatin C in pregnancy, but the test may be ordered at physician discretion when creatinine is ambiguous [17].

Frequently asked questions

›What is a normal cystatin C level?
The standard adult reference interval is 0.62 to 1.15 mg/L, though some labs use 0.50 to 1.20 mg/L depending on assay calibration. Values tend to rise slightly with age: adults over 65 may have upper-normal values up to 1.30 mg/L. Results should always be interpreted alongside the CKD-EPI cystatin C eGFR, not the raw concentration alone.
›What does a high cystatin C mean?
A cystatin C above 1.15 to 1.20 mg/L suggests reduced glomerular filtration rate. Before attributing this to kidney disease, rule out hyperthyroidism, high-dose corticosteroid use, and active systemic inflammation, all of which can raise cystatin C independently of GFR. If those are excluded, a high result typically confirms or upgrades a CKD diagnosis and warrants nephrology evaluation.
›What does a low cystatin C mean?
A cystatin C below 0.62 mg/L is uncommon. It may reflect hyperfiltration (early diabetic nephropathy), low body weight, or hypothyroidism suppressing production. Hyperfiltration with a low cystatin C is still a risk factor for future kidney disease, so urine albumin testing is warranted even when the number looks favorable.
›Is cystatin C better than creatinine for measuring kidney function?
In most clinical situations, yes. A 2021 NEJM validation study (N=1,434) showed the combined creatinine-cystatin C CKD-EPI 2021 equation estimated measured GFR within 30% in 92.7% of participants, versus 88.3% for creatinine alone. Cystatin C is especially superior in patients with low muscle mass, obesity, or ages above 65.
›How do you lower cystatin C levels?
The most effective approach is slowing CKD progression through blood pressure control (target below 120/80 mmHg), SGLT2 inhibitors in diabetic CKD (canagliflozin reduced CKD progression by 30% in CREDENCE), ACE inhibitors or ARBs, and dietary protein restriction to 0.6 to 0.8 g/kg/day. If elevation is partly driven by hyperthyroidism or corticosteroids, treating those conditions may reduce cystatin C within 6 to 12 weeks.
›Can inflammation falsely raise cystatin C?
Yes. Active inflammation with CRP above 10 mg/L can raise cystatin C by 0.05 to 0.15 mg/L above the GFR-attributable level. Always check a CRP or ESR when systemic illness or autoimmune disease is active. The KDIGO guidelines acknowledge inflammation as a recognized non-GFR determinant of cystatin C.
›Does cystatin C require fasting?
No. Food intake does not meaningfully affect serum cystatin C concentration. The test can be drawn at any time of day alongside a routine metabolic panel.
›What medications falsely raise cystatin C?
High-dose corticosteroids (prednisone above 10 mg/day) are the best-documented pharmacological cause. They increase cellular cystatin C production independently of GFR. Thyroid hormone excess from exogenous levothyroxine overdose or Graves disease also raises cystatin C. Ciclosporin and tacrolimus may raise it through combined renal and non-renal mechanisms.
›Should cystatin C be used for AKI detection?
Cystatin C rises approximately 24 to 48 hours earlier than creatinine during acute kidney injury, making it a promising early marker. It is not yet in the standard AKI diagnostic criteria (KDIGO AKI 2012 uses creatinine and urine output), but many centers use it alongside NGAL and KIM-1 in high-risk ICU or post-operative patients.
›What CPT code is used for cystatin C?
CPT code 82610 covers serum cystatin C measurement. Insurance coverage varies; Medicare Part B generally covers it when ordered for CKD evaluation with a supporting ICD-10 diagnosis code such as N18.3 (CKD stage 3).
›How often should cystatin C be repeated?
KDIGO recommends confirming any single eGFR-based CKD diagnosis with a repeat test at least 90 days apart. For stable CKD G3, annual cystatin C is reasonable. In AKI monitoring or during nephrotoxic drug therapy, repeat every 24 to 48 hours is appropriate.

References

  1. Shlipak MG, Sarnak MJ, Katz R, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med. 2005;352(20):2049 to 2060. https://www.nejm.org/doi/10.1056/NEJMoa043161
  2. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117, S314. https://pubmed.ncbi.nlm.nih.gov/38490803/
  3. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604 to 612. https://pubmed.ncbi.nlm.nih.gov/19414839/
  4. American Diabetes Association Professional Practice Committee. Standards of Medical Care in Diabetes, 2023. Diabetes Care. 2023;46(Suppl 1):S1, S291. https://diabetesjournals.org/care/issue/46/Supplement_1
  5. Herget-Rosenthal S, Marggraf G, Hüsing J, et al. Early detection of acute renal failure by serum cystatin C. Kidney Int. 2004;66(3):1115 to 1122. https://pubmed.ncbi.nlm.nih.gov/15327406/
  6. Anderson AH, Yang W, Hsu CY, et al. Predictors of measured glomerular filtration rate in the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis. 2012;60(5):736 to 746. https://pubmed.ncbi.nlm.nih.gov/22727938/
  7. Rule AD, Kremers WK, Lorenz EC, et al. Comparison of measured and estimated GFR in healthy potential kidney donors. Am J Kidney Dis. 2013;62(3):471 to 477. https://pubmed.ncbi.nlm.nih.gov/23769137/
  8. Stevens LA, Coresh J, Schmid CH, et al. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis. 2008;51(3):395 to 406. https://pubmed.ncbi.nlm.nih.gov/18295055/
  9. Inker LA, Eneanya ND, Coresh J, et al. New creatinine- and cystatin C-based equations to estimate GFR without race. N Engl J Med. 2021;385(19):1737 to 1749. https://www.nejm.org/doi/10.1056/NEJMoa2102953
  10. Knight EL, Verhave JC, Spiegelman D, et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int. 2004;65(4):1416 to 1421. https://pubmed.ncbi.nlm.nih.gov/15086483/
  11. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy (CREDENCE). N Engl J Med. 2019;380(24):2295 to 2306. https://www.nejm.org/doi/10.1056/NEJMoa1811744
  12. Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes (FIDELIO-DKD). N Engl J Med. 2020;383(23):2219 to 2229. https://www.nejm.org/doi/10.1056/NEJMoa2025845
  13. SPRINT Research Group; Wright JT Jr, Williamson JD, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103 to 2116. https://www.nejm.org/doi/10.1056/NEJMoa1511939
  14. Huang X, Jiménez-Moleón JJ, Lindholm B, et al. Mediterranean diet, kidney function, and mortality in men with CKD. Clin J Am Soc Nephrol. 2013;8(9):1548 to 1555. https://pubmed.ncbi.nlm.nih.gov/23744003/
  15. Shlipak MG, Katz R, Sarnak MJ, et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med. 2006;145(4):237 to 246. https://pubmed.ncbi.nlm.nih.gov/16908914/
  16. Lassus JP, Harjola VP, Sund R, et al. Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP. Eur Heart J. 2007;28(15):1841 to 1847. https://pubmed.ncbi.nlm.nih.gov/17586831/
  17. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 203: Chronic Hypertension in Pregnancy. Obstet Gynecol. 2024. https://www.acog.org/clinical/clinical-guidance/practice-bulletin/articles/2019/01/chronic-hypertension-in-pregnancy